Featured news in The Life Sciences Report



BrainStorm Cell Therapeutics Inc. (BCLI:NASDAQ)
BrainStorm Cell Therapeutics Announces Outcome of FDA Meeting on NurOwn® in ALS (12/7/2023)

view
 

BrainStorm Cell Therapeutics Inc. (BCLI:NASDAQ)
BRAINSTORM INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Brainstorm To Contact Him Directly To Discuss Their Options (12/7/2023)

view
 

BrainStorm Cell Therapeutics Inc. (BCLI:NASDAQ)
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Brainstorm Cell Therapeutics Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - BCLI (12/7/2023)

view
 

BrainStorm Cell Therapeutics Inc. (BCLI:NASDAQ)
SHAREHOLDER ALERT: Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of January 2, 2024 in Brainstorm Cell Lawsuit - BCLI (12/7/2023)

view
 

BrainStorm Cell Therapeutics Inc. (BCLI:NASDAQ)
SHAREHOLDER ALERT: Contact Levi & Korsinsky Before January 2, 2024 to Discuss Your Rights - BCLI (12/7/2023)

view
 

BrainStorm Cell Therapeutics Inc. (BCLI:NASDAQ)
BRAINSTORM SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Brainstorm To Contact Him Directly To Discuss Their Options (12/5/2023)

view
 

BrainStorm Cell Therapeutics Inc. (BCLI:NASDAQ)
ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Encourages Brainstorm Cell Therapeutics Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - BCLI (12/5/2023)

view